Icon
+91 94997 68112
Login Register

Verquvo - (2.5 mg ; Tablet)

Vericiguat MSD
2.5 mg ; Tablet
Less Than $1000 mn
None None
More Than 5
 None
None None
VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Yes
*** **** ****** - **-***-****
Verquvo Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
******* *******
  1. *** **, **** : * **** ** ** ***** *** ***** *** **** ****.

Verquvo - (5 and 10 mg ; Tablet)

Vericiguat MSD
5 and 10 mg ; Tablet
Less Than $1000 mn
None None
More Than 5
 None
None None
VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Yes
*** **** ****** - **-***-****
Verquvo Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
******* *******
  1. *** **, **** : * **** ** ** ***** *** ***** *** **** ****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.